Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep 1;22(3):238-243.
doi: 10.5935/1518-0557.20180039.

Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial

Maryam Eftekhar  1   2 , Ramesh Baradaran Bagheri  1   2 , Nosrat Neghab  1   2 , Robabe Hosseinisadat  3
Affiliations
Randomized Controlled Trial

Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial

Maryam Eftekhar et al. JBRA Assist Reprod. .

Abstract

Objective: This study aimed to evaluate the effect of three days of GnRH antagonist pretreatment on the pregnancy outcomes of women with polycystic ovarian syndrome (PCOS) on GnRH antagonist protocols for IVF/ICSI.

Methods: Fifty women with PCOS in the control group received conventional antagonist protocols, starting on day 2 of the cycle. In the pretreatment group (n=38), a GnRH antagonist was administered from day 2 of the menstrual cycle for three days.

Results: Controlled ovarian stimulation (COS) duration and gonadotropin dosages were similar in both groups. The number of metaphase II (MII) oocytes, 2PN oocytes, embryos, along with implantation and clinical pregnancy rates, were higher in the pretreatment group when compared with controls, although the increment was not significant (P value ≥0.05). The chemical pregnancy rate was significantly higher in the pretreatment group. The rate of OHSS was significantly lower in the pretreatment than in the control group.

Conclusion: Women with PCOS offered early follicular phase GnRH antagonist pretreatment for three consecutive days had significantly fewer cases of OHSS and higher chemical pregnancy rates. There were trends toward greater numbers of MII oocytes, 2PN oocytes, and embryos, and higher clinical pregnancy rates in the pretreatment group.

Keywords: assisted reproductive technology; gonadotropins; polycystic ovarian syndrome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors of this article have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Schematic view of cetrotide pretreatment protocol.
Figure 2
Figure 2
Consort flowchart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, Devroey P. Hum Reprod. Vol. 15. European Cetrorelix Study Group; 2000. Ovarian stimulationwith HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin; pp. 526–531. - DOI - PubMed
    1. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006;3:CD001750. doi: 10.1002/14651858.CD001750.pub2. - DOI - PubMed
    1. Blockeel C, Riva A, De Vos M, Haentjens P, Devroey P. Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study. Fertil Steril. 2011a;95:1714-9.e1-2. doi: 10.1016/j.fertnstert.2011.01.028. - DOI - PubMed
    1. Blockeel C, Baumgarten M, De Vos M, Verheyen G, Devroey P. Administration of GnRH antagonists in case of elevated progesterone at initiation of the cycle: a prospective cohort study. Curr Pharm Biotechnol. 2011b;12:423–428. doi: 10.2174/138920111794480633. - DOI - PubMed
    1. Borm G, Mannaerts B. Hum Reprod. Vol. 15. The European Orgalutran Study Group; 2000. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicenter trial; pp. 1490–1498. - DOI - PubMed

Publication types

MeSH terms